View Older Stories View More Recent Stories
-
NRx Pharmaceuticals to submit 70,000 patient ketamine data to FDA
-
NRx Pharmaceuticals partners with neurocare for mental health clinics
-
NRx Pharmaceuticals eliminates all debt through $5.4 million equity conversion
-
NRx Pharmaceuticals (NRXP) files $150M mixed shelf
-
NRx Pharmaceuticals receives FDA review for preservative-free ketamine
-
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
HOPE Therapeutics launches one-day depression treatment in Florida
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
NRx Pharmaceuticals re-files drug application for preservative-free ketamine
-
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of
-
NRx Pharmaceuticals receives FDA approval for preservative-free ketamine
-
NRx Pharmaceuticals completes Dura Medical acquisition
-
H.C. Wainwright Assumes NRx Pharmaceuticals (NRXP) at Buy, 'A Paradigm Shift in the Treatment of Depression With Suicidality'
-
New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company (NASDAQ: TONX), Laser Photonics (NASDAQ: LASE), Sullivan & Cromwell Senior M&A Partner Fra
-
NRX Pharmaceuticals launches expanded access for ketamine treatment
-
NRx Pharmaceuticals, Inc. (NRXP) PT Raised to $34 at D. Boral Capital
-
NRx Pharmaceuticals, Inc. (NRXP) PT Raised to $21 at BTIG
-
NRx Pharmaceuticals receives FDA fast track status for suicide treatment
-
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation
-
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
-
HOPE Therapeutics receives Florida approval for Dura Medical acquisition
-
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns
-
New to The Street Show #680 to Air Saturday, July 26 at 6:30 PM EST on Bloomberg TV
-
NRx Pharmaceuticals (NRXP) and HOPE Announce Agreement to Acquire Interest in Cohen and Associates
-
NRx Pharmaceuticals (NRXP) Files $150M Mixed Shelf
-
New to The Street Show #673 Airs Nationwide on Bloomberg TV - Saturday, June 21 at 6:30 PM EST Featuring FLOKI, NRX Pharmaceuticals (NASDAQ:NRXP), MUSQ - The Music ETF (NYSE:MUSQ), Health In Tech (NAS
-
New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST
-
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ:
-
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
-
NRx Pharmaceuticals (NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine
-
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute
-
NRx Pharmaceuticals (NRXP) Files Patent Application for NRX-100
-
NRx Pharmaceuticals (NRXP) and HOPE Sign Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
-
BTIG Starts NRx Pharmaceuticals, Inc. (NRXP) at Buy
-
NRx Pharmaceuticals (NRXP) and HOPE Announce Definitive Purchase Agreement with Dura Medical
-
NRx Pharmaceuticals (NRXP) and HOPE Therapeutics Sign LoI with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
NRx Pharmaceuticals (NRXP) and HOPE Therapeutics Execute Agreement for $27M Funding Transaction for HOPE Clinic Acquisition
-
NRx Pharmaceuticals (NRXP) Advances Relationship with Anson Funds with $8.9M Financing
-
NRx Pharmaceuticals (NRXP) Regains Nasdaq Compliance
-
NRx Pharmaceuticals (NRXP) Appoints Michael Taylor to its Board, Anita Nunes as Board Observer
-
NRx Pharmaceuticals (NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
NRx Pharmaceuticals (NRXP) Appoints Michael Abrams as Chief Financial Officer
-
NRx Pharmaceuticals (NRXP) Reschedules Q3 Call
-
NRx Pharmaceuticals' (NRXP) HOPE Therapeutics Announce Signing of a LoI to Acquire its First Florida Interventional Psychiatry Clinics
